Genmab — Oktober 2012
-
jeg tror ikke der er cash bekymringer tilbage
-
nu skal markedet bare finde ud af hvad fanden den skal ekstrapolere
-
de sparer 80 på zalu alene
-
nej det er zalu
-
de lavede det her periodisering også for 2012
-
så zalu har 80 inden i budgettet i år også
-
det ligger i aka´s erindring....ikke i hukommelsen
-
vi spørger ham næste uge
-
Angående Campath - er Arzerra den naturlige tager af dette marked ? Der vil jo være et named patient program, hvor Campath gives til de patienter der ønsker det - dog menes jeg at have læst, at det er lettere besværligt. Nogen der husker hvad Campath omsatte for i CLL ?
-
men så vil det blive som offlabel?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind